Inflammatory bowel diseases and management considerations: fertility and pregnancy.
Young women with inflammatory bowel disease (IBD) pose a unique set of challenges. These women and their treating physicians must make difficult choices in matters regarding conception, pregnancy, and breastfeeding. This review highlights recent evidence and management issues that arise when taking care of women with IBD in terms of fertility, outcomes, and medication safety in pregnancy and breastfeeding. Ultimately, treatment must be individualized for each patient based on the available evidence and the woman's preferences.
Moscandrew
Maria
M
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Kane
Sunanda
S
D000818:Animals; D001379:Azathioprine / Q000627:therapeutic use; D001942:Breast Feeding; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005260:Female; D005298:Fertility / Q000187:drug effects*; D005765:Gastrointestinal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007247:Infertility, Female / Q000209:etiology; D015212:Inflammatory Bowel Diseases / Q000150:complications / Q000188:drug therapy*; D015122:Mercaptopurine / Q000627:therapeutic use; D015201:Meta-Analysis as Topic; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011256:Pregnancy Outcome; D012307:Risk Factors
D005765:Gastrointestinal Agents; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D015122:Mercaptopurine; D001379:Azathioprine